-
Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Gender Differences in the Economic Burden of Alcohol Use in Belgium
Sep 9, 2025, 16:22 PM -
Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial
Sep 9, 2025, 16:22 PM -
Assessing Patient Access to Psoriasis Treatments in Central, South, and Eastern European Countries: Insights and Disparities?
Sep 9, 2025, 16:22 PM -
Burden of Disease in Hereditary Transthyretin Amyloidosis With Polyneuropathy in Spain
Sep 9, 2025, 16:22 PM -
Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy
Sep 9, 2025, 16:22 PM -
Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK
Sep 9, 2025, 16:22 PM -
A Case Study: How England Implemented Its First Population Health Agreement
Sep 9, 2025, 16:22 PM -
Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?
Sep 9, 2025, 16:22 PM -
Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study
Sep 9, 2025, 16:22 PM -
Quantifying the Therapeutic Benefit of External Beam Radiotherapy in Uterine Serous Carcinoma: A Real-World Study
Sep 9, 2025, 16:22 PM -
Developing the Next Generation of Therapeutics: The Role of Early Model-Based Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Persistence to Basal Insulin and Economic Outcomes Among Patients With Type 2 Diabetes: A Retrospective Analysis Using Electronic Health Records in England
Sep 9, 2025, 16:22 PM -
Epidemiology and Demographic Characteristics of Phenylketonuria in Brazil: A Real-World Data Study (2019-2024)
Sep 9, 2025, 16:22 PM -
What Are the Biggest Value Drivers? A Comparison of the Relative Impacts of Six Novel Value Elements on Value Estimates Across Twelve Treatments Through Generalized Cost-Effectiveness Analyses
Sep 9, 2025, 16:22 PM -
Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal
Sep 9, 2025, 16:22 PM -
The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece
Sep 9, 2025, 16:22 PM -
Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland
Sep 9, 2025, 16:22 PM -
Quality of Life and Productivity Costs in Cancer Patients Receiving Proton Therapy: A Predictive and Descriptive Study
Sep 9, 2025, 16:22 PM
